ADP-600

N/A

Report date: 2025/03/18 13:51:02

Base Information

Drug NameADP-600
Drug Alias NameADP-600
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionMelanoma antigen preferentially expressed in tumors modulators
TargetsMelanoma antigen preferentially expressed in tumors
Therapy Area/IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAdaptimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesAdaptimmune Llc
Inactive CompaniesN/A
Active IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A